Despite facing a patent cliff of up to $300 billion by 2030 and knowing that most innovation is externally sourced, big pharma's M&A activity remains surprisingly tepid. This paradox suggests a major disconnect between strategic necessity and the industry's current risk appetite or deal-making capacity.

The nature of biopharma M&A changed dramatically in a year. After a period with no deals over $5 billion, there are now seven or eight such transactions, reflecting a pivot by large pharma to acquire de-risked assets with large market potential to offset looming patent expirations.

Despite a seemingly active year for M&A, pharmaceutical companies only addressed less than 17% of their upcoming revenue shortfall from patent expirations. This mathematical reality indicates that the pace of M&A activity must accelerate significantly in the coming years simply to maintain current revenue levels.

The recent biotech funding "winter" thawed as large pharmaceutical companies began addressing their massive patent cliffs. This existential threat spurred a wave of M&A transactions, which in turn injected capital and confidence back into the market, enabling smaller biotechs to raise funds through follow-on offerings and IPOs.

Large pharmaceutical companies face losing up to 50% of their revenues by 2030 due to the largest patent expiration wave in history. To survive, they will be forced to acquire innovation from the biotechnology sector, fueling a sustained M&A cycle for years to come.

Despite a slower start to the year, the fundamental drivers for M&A remain strong. Barclays' M&A head notes that pharmaceutical companies face near-term patent expirations and have ample capital, ensuring that dealmaking will persist in cycles rather than structurally decline.

Competitive bidding wars for biotech companies are not isolated incidents. They are a clear indicator of heightened market aggression and the intense pressure large pharmaceutical firms feel to acquire assets and drive growth ahead of major patent expirations.

Widespread conservative 2026 guidance across biopharma is not driven by anticipated tariffs or policy changes. Instead, companies are finally feeling the direct impact of the long-discussed "patent cliff," with multiple major firms citing imminent losses of exclusivity (LOEs) for their blockbuster drugs as the primary headwind.

With patent cliffs looming and mature assets acquired, large pharmaceutical companies are increasingly paying billion-dollar prices for early-stage and even preclinical companies. This marks a significant strategic shift in M&A towards accepting higher risk for earlier innovation.